Mots-clés  Néphrite lupique, traitement, cible, polyarthrite rhumatoïde, diagnostic, prise en charge

Farah Tamirou, Charlotte Baert, Pauline Montigny, Frédéric A. Houssiau, Emilie Sapart, Aleksandra Avramovska, Laurent Meric de Bellefon, Stéphanie de Montjoye, Stéphanie Dierckx, Adrien Nzeusseu, Valérie Pirson, Tatiana Sokolova, Maria Stoenoiu, Patrick D Published in the journal : February 2022 Category : Rheumatology

Summary :

The current standard of care for lupus nephritis has so far been based on sequential immunosuppressive therapy aimed to induce a response, called induction therapy, and to prevent relapse, called maintenance therapy. The results of this approach are deemed unsatisfactory, with only 20-30% of complete renal responses observed at 6-12 months, with at least 20% of patients suffering from chronic kidney failure and 5-20% from end-stage kidney disease at 10 years post-diagnosis. Herein, we have briefly discussed two new treatments, consisting of belimumab and voclosporin, recently registered by drug agencies in the aftermath of controlled trials that demonstrated their superiority given in addition to standard immunosuppressive therapy. Further progress in rheumatoid arthritis is being based on further integrating goals, such as monitoring patients' daily symptoms and well managing co-morbidities like cardiovascular disease. An improved understanding of its pathophysiology has enabled translational research designed to develop new therapeutic strategies including numerous targeted biological and synthetic agents.

Key Words

Lupus nephritis, treatment, target, rheumatoid arthritis, diagnosis, daily care